- Home
- ATNM vs NXN Comparison
ATNM vs NXN Comparison
Compare ATNM & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATNM | NXN |
|---|---|---|
| Founded | 2000 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 47.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ATNM | NXN |
|---|---|---|
| Price | $1.38 | $12.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 223.5K | 9.7K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $90,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $48.42 |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $1.03 | $10.64 |
| 52 Week High | $2.41 | $12.45 |
Technical Indicators
Market Signals| Indicator | ATNM | NXN |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 45.86 |
| Support Level | $1.25 | $11.98 |
| Resistance Level | $1.48 | $12.25 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 35.85 | 30.00 |
Price Performance
Historical ComparisonAbout ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.